Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020).


Journal

Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250

Informations de publication

Date de publication:
Historique:
received: 26 03 2020
revised: 27 03 2020
accepted: 27 03 2020
pubmed: 17 4 2020
medline: 24 7 2020
entrez: 17 4 2020
Statut: ppublish

Résumé

and Aims: No valid treatment or preventative strategy has evolved till date to counter the SARS CoV 2 (Novel Coronavirus) epidemic that originated in China in late 2019 and have since wrought havoc on millions across the world with illness, socioeconomic recession and death. This analysis was aimed at tracing a trend related to death counts expected at the 5th and 6th week of the COVID-19 in India. Validated database was used to procure global and Indian data related to coronavirus and related outcomes. Multiple regression and linear regression analyses were used interchangeably. Since the week 6 death count data was not correlated significantly with any of the chosen inputs, an auto-regression technique was employed to improve the predictive ability of the regression model. A linear regression analysis predicted average week 5 death count to be 211 with a 95% CI: 1.31-2.60). Similarly, week 6 death count, in spite of a strong correlation with input variables, did not pass the test of statistical significance. Using auto-regression technique and using week 5 death count as input the linear regression model predicted week 6 death count in India to be 467, while keeping at the back of our mind the risk of over-estimation by most of the risk-based models. According to our analysis, if situation continue in present state; projected death rate (n) is 211 and467 at the end of the 5th and 6th week from now, respectively.

Identifiants

pubmed: 32298982
pii: S1871-4021(20)30057-6
doi: 10.1016/j.dsx.2020.03.017
pmc: PMC7128942
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-315

Informations de copyright

Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None to declare.

Références

Curr Top Microbiol Immunol. 2005;287:1-30
pubmed: 15609507
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Lancet Public Health. 2020 May;5(5):e256
pubmed: 32199471

Auteurs

Samit Ghosal (S)

Consultant Endocrinologist. Nightingale Hospital, Kolkata, India. Electronic address: ramdasghosal@gmail.com.

Sumit Sengupta (S)

Consultant Pulmonologist. AMRI Hospitals, Kolkata, India.

Milan Majumder (M)

Milan Majumder, Independent Statistician, Pune, India.

Binayak Sinha (B)

Consultant Endocrinologist. AMRI Hospitals, Kolkata, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH